Pulse Biosciences, Inc.
HealthcareNASDAQ:PLSE · NASDAQ Capital Market
-$2.52 today
Vol 0.40M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-90.2%
avg 150.4%
ROIC
-85.7%
avg -78.9%
ROA
-75.7%
avg -70.0%
Analysis
ROA is currently the strongest return metric at -75.7% versus its period average of -70.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Darrin R. Uecker | Chief Technology Officer & Director | $869,889.00 | — | 60 | $100,000.00 | 0.14% |
Paul Arthur LaViolette | President, Chief Executive Officer & Co-Chairman of the Board | $765,068.00 | — | 68 | $15,846.00 | 0.02% |
Jon Skinner | Chief Financial Officer | $459,898.00 | — | 40 | — | — |
David Kenigsberg | Chief Medical Officer | — | — | — | — | — |
Gansevoort Dunnington | Chief Medical Officer | — | — | — | — | — |
Niv Ad | Chief Science Officer of Cardiac Surgery | — | — | — | — | — |
David Danitz | Senior Vice President of Engineering | — | — | — | — | — |
Kenneth Stratton | General Counsel & Corporate Secretary | — | — | 57 | $20,000.00 | 0.03% |
Steven T. Weber | Vice President of Accounting, Principal Accounting Officer & Global Corporate Controller | — | — | 50 | $0.00 | <0.01% |
Liane Teplitsky | Chief Operating Officer | — | — | 49 | — | — |
Patty Perla | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$27.10M
Sells
16
$5.49M
Net Sentiment
+$21.61M
Net buying
Most Active
Danahy Kevin Patrick
10 transactions
1–10 of 21
Analysis
Insiders reported 5 buys worth $27.10M and 16 sells worth $5.49M over the last 12 months. That adds up to net buying of $21.61M. Danahy Kevin Patrick was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Beta Bionics, Inc.
NASDAQ:BBNX
$647.48M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Who manages PLSE?
Pulse Biosciences, Inc. (PLSE) lists 11 active executives. The top listed executive is Darrin R. Uecker, Chief Technology Officer & Director.
Are PLSE insiders buying or selling?
Recent insider activity shows net buying of $245.50M.
Explore More
Continue the stock analysis
Jump to another research area for this company.